Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rubicon Genomics has selected Velesco Pharmaceutical Services to manufacture the TransPLEX kits for use with Agendia's breast cancer diagnostics.
Subscribe to our email newsletter
The terms of the manufacturing agreement have not been disclosed.
Velesco operates a 10,000ft2 cGMP manufacturing facility in Kalamazoo, Michigan.
Rubicon has signed a clinical supply agreement with Agendia for its TransPLEX whole genome RNA amplification technology.
Agendia is using Rubicon’s kits to facilitate the analysis of formalin-fixed, paraffin-embedded patient samples for use with its Symphony breast cancer diagnostics.
Rubicon CEO James Koziarz said the company has found a qualified manufacturing partner located near its headquarters in Ann Arbor.
"Velesco’s cGMP facility and quality processes are first-rate; its quality track record is impeccable and it has the formulation, fill and finishing expertise we need," Koziarz added.
"Velesco provides us an immediate pathway to cGMP kits for diagnostic use and it has the capacity to rapidly expand cGMP production as sales of our diagnostic kits ramp up."